Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

Viruses. 2021 Nov 19;13(11):2313. doi: 10.3390/v13112313.

Abstract

Background: Dynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic.

Methods: Workers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in the study. Virus-specific IgG and IgM were monitored 2, 6 and 13 months after the outbreak via rapid IgG/IgM serological test and SARS-CoV-2 S protein-specific IgG ELISA.

Results: Six months after the outbreak, 95% (CI 86-99%) of 59 previously infected individuals had virus-specific antibodies irrespective of the severity of infection. One-third of seropositive individuals had virus-specific IgM along with IgG indicating that IgM may persist for 6 months. Serological testing 13 months after the outbreak included 47 recovered individuals that remained non-vaccinated despite a wide accessibility of COVID-19 vaccines. The seropositivity rate was 83% (CI 69-91%) excluding one case of confirmed asymptomatic reinfection in this group. Between months 6 and 13, IgG levels either declined or remained stable in 31 individual and increased in 7 individuals possibly indicating an exposure to SARS-CoV-2 during the second wave of the pandemic.

Conclusions: Detectable levels of SARS-CoV-2-specific antibodies persist up to 13 months after infection for the majority of the cases.

Keywords: IgG/IgM dynamics; SARS-CoV-2; longitudinal study; serological monitoring.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / blood*
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • COVID-19 Nucleic Acid Testing
  • COVID-19 Serological Testing
  • COVID-19 Vaccines
  • Cohort Studies
  • Disease Outbreaks
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Lithuania / epidemiology
  • Male
  • Middle Aged
  • SARS-CoV-2 / immunology*
  • Seroepidemiologic Studies
  • Time Factors
  • Young Adult

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Immunoglobulin M